Hypertension Initiation and Titration
Which antihypertensive to start, at what dose, and when to step up · v1.9- Enter the blood pressure, the age and sex, any compelling indication, and the current drugs with their doses.
- You get the pressure graded, the target this tool works to, and the next step in initiation or titration.
- It works to 130/80 mmHg, and to 140/80 above 65 years, which is its own setting rather than any one guideline's target.
- Beside that it prints what IGH-V, the ICMR Standard Treatment Workflow and the InSH consensus would each call this pressure and what target each would set.
- All three are current, they define hypertension at different numbers, and the tool resolves none of it.
- It flags contraindications, doses already at the maximum and the diastolic floor, and routes pregnancy, lactation and crisis out of the standard pathway.
- The hypertensive emergency, where the rate of lowering matters more than the choice of agent.
- The diagnosis of secondary hypertension. It says when to go looking, and Evidence and Pearls gives the clue and the screening test for each cause.
- Children and adolescents. The age field starts at 18.
- Titration in pregnancy or lactation, and the management of pre-eclampsia. It flags both states and names the safe and the contraindicated agents, and the rest is obstetric care.
1. Patient Vitals & Demographics
2. Compelling Indications & Flags
3. Current Pharmacotherapy (Leave blank if treatment-naïve)
Pathway Architecture and Clinical Pearls
1. The Size of the Problem in India, and What to Screen at Baseline
India carries the world’s largest absolute burden of hypertension. The ICMR-INDIAB study (2023) estimated that over 315 million Indians are hypertensive, yet fewer than 1 in 10 have their blood pressure adequately controlled. Hypertension is the single largest contributor to cardiovascular death in India.
South Asians develop hypertension at a younger age and carry more target organ damage per mmHg of elevation, and the PURE study confirmed that they suffer cardiovascular events at a lower BP threshold. Early and aggressive guideline-directed treatment therefore matters more in this population, not less. Screen every newly diagnosed patient for end-organ damage: many Indian patients present late, and detection of organ damage upgrades CV risk and mandates pharmacotherapy regardless of BP grade.
| Organ | Investigation & Findings |
|---|---|
| Heart | ECG, Echo: LVH, diastolic dysfunction, wall motion abnormalities |
| Kidney | Creatinine, eGFR, Urine ACR: eGFR < 60 or ACR > 30 mg/g |
| Eye | Fundoscopy: Hypertensive retinopathy (KW Grade 2+) |
| Vessels | Carotid Doppler: IMT > 0.9 mm or carotid plaque |
| Brain | Clinical: Prior TIA, stroke, cognitive decline |
2. What Counts as Hypertension: Three Current Indian Answers
Three Indian guidelines published in 2025 and 2026 are all current, and they do not agree on the number at which a person becomes hypertensive. Two say 140/90 and one says 130/80. Take the patient at 134/86. That is Stage 1 hypertension to the Indian Society of Hypertension. To the national workflow and to IGH-V it is elevated blood pressure and explicitly not hypertension. Whether that person is told they have a disease depends on which document is open.
| Document | Hypertension begins at | Bands | Treated target |
|---|---|---|---|
| IGH-V, Association of Physicians of India with the Indian College of Physicians, the Cardiological Society of India and the Hypertension Society of India. JAPI 74(5), May 2026 | 140/90, stated against the ACC/AHA change: it will continue with the previous definition | Its classification table is not reproduced here, because it was not read | Below 60 years, 130/80. Sixty and above, 130-140 / 80-90 |
| ICMR Standard Treatment Workflow: Hypertension in Adults, May 2026 | 140/90 on two clinic visits; one visit suffices at 160/100 | Normal <120 and <80. Elevated 120-139 and/or 80-89. Grade 1 140-159 and/or 90-99. Grade 2 160-179 and/or 100-109. Grade 3 ≥180 and/or ≥110 | All adults <140/90. Diabetes, CKD or established CVD <130/80 if tolerated. Eighty years and above <150/90 |
| InSH consensus, Indian Society of Hypertension. Hypertension Journal 11(4), 2025 | 130/80 on repeated office measurement | Normal <120 and <80. Raised 120-129 and <80. Stage 1 130-139 and/or 80-89. Stage 2 ≥140 and/or ≥90 | Most adults <130/80. Diabetes, CKD or CVD 120-129 / 70-79. Older or frail, individualised |
They disagree about the label more than about the destination. A 52 year old with no comorbidity is aimed at 130/80 by IGH-V and by InSH, and at 140/90 by the national workflow, so the argument that actually reaches the prescription is whether to add a third drug at 138/86. The result panel prints all three positions for the patient you have entered.
Alongside those three, the tool displays the international grading below.
| Category | BP (mmHg) |
|---|---|
| Optimal | < 120 / < 80 |
| Normal | 120-129 / 80-84 |
| High Normal | 130-139 / 85-89 |
| Grade 1 (Mild) | 140-159 / 90-99 |
| Grade 2 (Moderate) | 160-179 / 100-109 |
| Grade 3 (Severe) | ≥ 180 / ≥ 110 |
| Isolated Systolic | ≥ 140 / < 90 |
- Where systolic and diastolic values fall into different categories, the higher category takes precedence. Isolated systolic hypertension is common in the elderly and carries significant stroke risk.
- ESC 2024 does not use this structure. It adds an “elevated blood pressure” band of 120 to 139 over 70 to 89, and it sets a treated target of 120 to 129 systolic where the patient tolerates it. This tool does not apply that target.
- The tool works to 130/80 mmHg, and to 140/80 above 65 years. Those figures now sit inside the Indian range rather than outside it: IGH-V sets 130/80 below 60 years, and 130 to 140 over 80 to 90 from 60. They remain the tool’s own setting, they are tighter than the national workflow for a patient without comorbidity, and they are stated here so that you can see what you are being held to.
3. Measuring the Pressure, and the Two Ways the Office Reading Misleads
Correct BP measurement is the single most under-practised skill in Indian clinical practice. Incorrectly measured BP leads to misdiagnosis. The ISH 2020 guidelines provide a clear protocol.
| Preparation | Rest 5 min. Empty bladder. No coffee/tea/smoking 30 min prior. No talking. |
| Positioning | Seated, back supported, feet flat. Arm at mid-heart level. Legs uncrossed. |
| Cuff Size | Bladder encircles 75-100% of arm. Too small = falsely overestimates BP. |
| Technique | Take 3 readings, 1-2 min apart. Discard 1st. Average 2nd and 3rd. |
| Both Arms | Measure both at first visit. Difference > 15 mmHg = suspect subclavian stenosis. |
| Pattern | Office against home or ABPM | Risk | Action |
|---|---|---|---|
| White Coat HTN (~15-30%) | Office BP high, home/ABPM normal | Low to intermediate | Lifestyle modifications, annual monitoring. Avoid unnecessary drug therapy. |
| Masked HTN (~10-15%) | Office BP normal, home/ABPM high | Similar to sustained HTN, and often missed | Requires pharmacotherapy. Confirm by HBPM or 24h ABPM. |
Practical tip for PHCs: If ABPM is unavailable (common in rural India), ask the patient to buy a validated upper-arm automatic BP monitor. Record readings twice daily (morning and evening) for 7 days. Average days 2-7. Home BP ≥ 135/85 mmHg confirms hypertension.
4. Starting and Stepping Up: A + C + D, and How Long Each Class Takes
The foundation of modern therapy relies on A (ACEi/ARB), C (CCB), and D (Thiazide/Like Diuretics). The 2024 guidelines heavily favour initiating with a Fixed Dose Combination (FDC) containing two drugs at low doses rather than maximising monotherapy.
The Single Pill Strategy: ISH 2020 and ESC 2024 both emphasise that a single-pill combination (FDC) is the preferred starting strategy for most adults. Monotherapy should only be considered for frail elderly patients or low-risk Grade 1 hypertension.
| Step | Strategy & Combination |
|---|---|
| Step 1 | Dual Therapy (FDC): ACEi/ARB + CCB or ACEi/ARB + Thiazide-like |
| Step 2 | Triple Therapy (FDC): ACEi/ARB + CCB + Thiazide-like Diuretic |
| Step 3 | Resistant HTN: Add Spironolactone 12.5 to 50 mg |
| Step 4 | Refractory HTN: Specialist referral. Rule out secondary causes. |
India has affordable single-pill FDCs available at PHCs and Jan Aushadhi Kendras. Using an FDC significantly improves adherence in resource-limited settings.
| FDC (Dual: A + C) | Strengths & Notes |
|---|---|
| Telmisartan + Amlodipine | 40/5, 80/5 mg. Most prescribed FDC in India. Excellent 24h coverage. |
| Olmesartan + Amlodipine | 20/5, 40/5 mg. Potent. Useful when Telmisartan is insufficient. |
| Telmisartan + Cilnidipine | 40/10, 80/10 mg. Lower pedal oedema (dual L/N-type blockade). |
| Ramipril + Amlodipine | 2.5/5, 5/5 mg. Preferred when ACEi desired (post-MI). |
| FDC (Triple: A + C + D) | Strengths & Notes |
|---|---|
| Telmi + Amlo + Chlorthalidone | 40/5/12.5 mg. The “ideal triple FDC” for step-up. |
| Olme + Amlo + HCTZ | 20/5/12.5 mg. Alternative where Chlorthalidone FDC unavailable. |
Knowing how long each class takes to reach full effect prevents premature dose escalation. Titrating too early exposes the patient to side effects without allowing the drug its full chance.
| Drug Class | Full Effect & Tip |
|---|---|
| Alpha Blockers | 1-2 days. Start at bedtime (first-dose syncope). |
| CCBs | 4-5 days. Reassess within a week. |
| Thiazides / Clonidine | 1 week. Recheck at 2 weeks. |
| ACEi / ARBs | 3 weeks. Do not uptitrate before 3-4 weeks. |
| Spironolactone | 4-6 weeks. Recheck K+ and creatinine at 1 and 4 weeks. |
| Beta Blockers | Variable. Monitor via heart rate reduction. |
5. Calcium Channel Blockers: The Indian Perspective
Why are newer CCBs so popular in India? Amlodipine is the global gold standard. Dose-dependent pedal oedema limits its tolerability. Indian prescribers favour dual and triple-channel blockers for less ankle swelling and better renal protection. With this much CKD and diabetes about, it is the renal protection that counts.
| CCB | Channel, Oedema & Renal Effect |
|---|---|
| Amlodipine | L-type only. High oedema (afferent > efferent dilation). Moderate renoprotection. |
| Cilnidipine | L/N-type. Low oedema, good renoprotection (dilates both arterioles). |
| Benidipine | T/L/N-type. Low oedema, excellent renoprotection. Reduced reflex tachycardia. |
| Efonidipine | L/T-type. Low oedema, excellent renoprotection. Also reduces heart rate. |
6. Resistant and Refractory Hypertension, and What to Exclude First
| Label | Definition | How common | First step |
|---|---|---|---|
| Resistant | BP above target despite 3 drugs (including a diuretic) at optimal doses | ~10-15% of treated hypertensives | Confirm adherence, exclude white-coat effect, then add Spironolactone |
| Refractory | BP uncontrolled despite 5 or more agents (including a long-acting thiazide and an MRA) | ~1-3%. Rare but dangerous | Immediate specialist referral for secondary cause evaluation |
Before labelling as resistant: Ensure the patient is truly adherent, measure BP correctly, rule out white-coat hypertension, and check for BP-raising medications (NSAIDs, oral contraceptives, steroids, decongestants, liquorice/mulethi).
| Agent | Mechanism |
|---|---|
| NSAIDs | Na+ retention, reduced renal prostaglandins. Raises SBP 5-10 mmHg. Blunts ACEi/ARBs. |
| Oral Contraceptives | Activate RAAS. Check BP before and at 3-6 month intervals. |
| Corticosteroids | Na+ and water retention. Even short courses raise BP. |
| Decongestants | Pseudoephedrine, Phenylephrine: direct sympathomimetic. Use saline spray instead. |
| Liquorice / Mulethi | Inhibits 11-beta-HSD2 = mineralocorticoid excess. Even small daily amounts cause hypokalaemic HTN. |
| Erythropoietin | CKD/dialysis. Raises BP via increased viscosity and endothelin. |
| Cyclosporine / Tacrolimus | Renal vasoconstriction. Near-universal HTN in transplant recipients. |
7. When to Suspect Secondary Hypertension
Screen when: onset < 30 or > 55 yrs, suddenly worsening BP, resistant/refractory HTN, disproportionate organ damage, or characteristic clues below.
| Cause | Clue & Screening Test |
|---|---|
| Primary Aldosteronism | Hypokalaemia, resistant HTN, adrenal incidentaloma. Test: Aldosterone-to-Renin Ratio. |
| Renal Artery Stenosis | Abdominal bruit, creatinine rise with ACEi/ARB, flash pulmonary oedema. Test: Renal Doppler. |
| Phaeochromocytoma | Paroxysmal HTN, headache, palpitations, sweating. Test: 24h urine metanephrines. |
| Sleep Apnoea | Obesity, snoring, daytime somnolence, non-dipping BP. Test: STOP-BANG, polysomnography. |
| Cushing Syndrome | Moon facies, striae, central obesity, diabetes. Test: Dexamethasone suppression test. |
| Coarctation | Young patient, upper limb HTN, weak femoral pulses. Test: Echo, CT aortogram. |
| Thyroid Disease | Hyperthyroid = wide pulse pressure. Hypothyroid = diastolic HTN. Test: TSH, free T3/T4. |
8. Lifestyle Change, in Indian Terms
| Intervention | Target & SBP Drop |
|---|---|
| Weight Loss | BMI < 23 (Asian cut-off). Waist: < 90 cm (M), < 80 cm (F). ~1 mmHg/kg. |
| Healthy Diet | DASH-equivalent: ragi, bajra, greens, dal, curd, fruits. Cut refined carbs/fried snacks. ~11 mmHg. |
| Reduce Sodium | < 5 g salt/day (1 tsp). Less pickles, papads, namkeens. ~5-6 mmHg. |
| Increase Potassium | Bananas, coconut water, spinach, dal, sweet potatoes. Caution in CKD. ~4-5 mmHg. |
| Exercise | 30-45 min brisk walking, 5 days/week. Yoga/pranayama: moderate evidence. ~5-8 mmHg. |
| Alcohol | ≤ 2 drinks/day (men), ≤ 1 (women). Avoid country liquor. ~4 mmHg. |
| Tobacco | Stop all: cigarettes, bidis, gutka, khaini, hookah. Reduces CV events independently. |
Practical dietary counsel for your patients: “Use half the salt while cooking. No extra salt at the table. Limit pickles to a small teaspoonful per meal. Replace 1 cup of tea with 1 glass of buttermilk (chaas) or tender coconut water. Eat at least 2 servings of fruit and 3 servings of vegetables daily.”
9. Hypertension in Pregnancy
ACEi, ARBs and ARNis are absolutely contraindicated. They cause renal agenesis, pulmonary hypoplasia, and foetal death. Atenolol causes severe IUGR and must also be avoided.
| SAFE | CONTRAINDICATED |
|---|---|
| Labetalol (first-line) | ACEi (all) |
| Nifedipine SR/ER | ARBs (all) |
| Methyldopa | ARNi (Sacubitril-Valsartan) |
| Hydralazine (IV, acute) | Atenolol (severe IUGR) |
| Spironolactone (anti-androgenic) |
10. Landmark Trials That Shaped This Pathway
| Trial | Key Finding |
|---|---|
| SPRINT (2015) | Intensive SBP < 120 reduced CV events and mortality by ~25% in high-risk non-diabetics. |
| ALLHAT (2002) | Chlorthalidone equivalent or superior to Amlodipine and Lisinopril. Doxazosin arm stopped (excess HF). |
| HOPE (2000) | Ramipril reduced CV events in high-risk patients even without marked BP elevation. |
| VALUE (2004) | Amlodipine produced earlier BP control vs. Valsartan, reinforcing speed of BP reduction. |
| ONTARGET (2008) | Telmisartan non-inferior to Ramipril. Dual RAS blockade increased renal events. |
| PATHWAY-2 (2015) | Spironolactone most effective add-on for resistant HTN, superior to bisoprolol and doxazosin. |
| PURE (2014) | South Asians have the highest CV event rate per mmHg BP elevation of any ethnic group globally. |
Abbreviations: ABPM (Ambulatory Blood Pressure Monitoring) · ACE (Angiotensin-Converting Enzyme) · ACEi (Angiotensin-Converting Enzyme Inhibitor) · ACR (Albumin-to-Creatinine Ratio) · AFib (Atrial Fibrillation) · ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) · API (Association of Physicians of India) · ARB (Angiotensin Receptor Blocker) · ARNi (Angiotensin Receptor-Neprilysin Inhibitor) · AT1 (Angiotensin II Type 1 Receptor) · AV (Atrioventricular) · BB (Beta-Blocker) · BMI (Body Mass Index) · BP (Blood Pressure) · BPH (Benign Prostatic Hyperplasia) · CAD (Coronary Artery Disease) · CCB (Calcium Channel Blocker) · CKD (Chronic Kidney Disease) · COPD (Chronic Obstructive Pulmonary Disease) · CT (Computed Tomography) · CV (Cardiovascular) · DASH (Dietary Approaches to Stop Hypertension) · DBP (Diastolic Blood Pressure) · DHP (Dihydropyridine) · DM (Diabetes Mellitus) · ECG (Electrocardiogram) · ED (Emergency Department) · eGFR (Estimated Glomerular Filtration Rate) · ESC (European Society of Cardiology) · FDC (Fixed-Dose Combination) · HBPM (Home Blood Pressure Monitoring) · HCTZ (Hydrochlorothiazide) · HF (Heart Failure) · HFrEF (Heart Failure with Reduced Ejection Fraction) · HOPE (Heart Outcomes Prevention Evaluation) · HTN (Hypertension) · ICMR (Indian Council of Medical Research) · ICMR-INDIAB (Indian Council of Medical Research India Diabetes Study) · ICU (Intensive Care Unit) · IGH-V (Indian Hypertension Guideline, Fifth Edition) · IHD (Ischaemic Heart Disease) · IMT (Intima-Media Thickness) · InSH (Indian Society of Hypertension) · ISH (International Society of Hypertension) · IUGR (Intrauterine Growth Restriction) · IV (Intravenous) · K⁺ (Potassium) · KW (Keith-Wagener Grading of Hypertensive Retinopathy) · LVH (Left Ventricular Hypertrophy) · MAP (Mean Arterial Pressure) · MI (Myocardial Infarction) · MRA (Mineralocorticoid Receptor Antagonist) · Na⁺ (Sodium) · NSAID (Non-Steroidal Anti-Inflammatory Drug) · ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) · PDE5 (Phosphodiesterase Type 5) · PHC (Primary Health Centre) · PPAR-gamma (Peroxisome Proliferator-Activated Receptor Gamma) · PURE (Prospective Urban Rural Epidemiology Study) · RAAS (Renin-Angiotensin-Aldosterone System) · RAS (Renin-Angiotensin System) · SBP (Systolic Blood Pressure) · SPRINT (Systolic Blood Pressure Intervention Trial) · SR/ER (Sustained Release / Extended Release) · STOP-BANG (Snoring, Tired, Observed Apnoea, Pressure, BMI, Age, Neck Circumference, Gender) · STW (Standard Treatment Workflow) · T3/T4 (Triiodothyronine / Thyroxine) · TIA (Transient Ischaemic Attack) · TSH (Thyroid Stimulating Hormone) · VALUE (Valsartan Antihypertensive Long-term Use Evaluation) · XL (Extended Release) · 11-beta-HSD2 (11-Beta-Hydroxysteroid Dehydrogenase Type 2)
References
- Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults. Hypertension. 2025. Published online 14 August 2025.
- Mehta N, Mathur G, Pal J, Taneja A, Wander GS, et al. Indian Hypertension Guideline V (IGH-V), 2025-2026. Association of Physicians of India, with the Indian College of Physicians, the Cardiological Society of India and the Hypertension Society of India. J Assoc Physicians India. 2026;74(5).
- Indian Council of Medical Research and Department of Health Research, Ministry of Health and Family Welfare, Government of India. Standard Treatment Workflow: Hypertension in Adults (ICD-11 BA00). New Delhi; May 2026.
- Gupta R, Maheshwari A, Verma N, Narasingan SN, Tripathi K, Joshi S, Manoria PC. Indian Society of Hypertension (InSH) Consensus Guideline for the Management of Hypertension, 2025. Hypertension Journal. 2025;11(4):76-138.
- McEvoy JW, et al. 2024 ESC Clinical Practice Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018.
- Unger T, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334-1357.
- Anjana RM, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5(8):585-596.
- Yusuf S, et al. Cardiovascular risk and events in 17 low-, middle-, and high-income countries (PURE Study). N Engl J Med. 2014;371(9):818-827.
- SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116.
- ALLHAT Officers. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-2997.
- Williams B, et al (PATHWAY-2). Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension. Lancet. 2015;386(10008):2059-2068.
- Yusuf S, et al (ONTARGET). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
- HOPE Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145-153.
- National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD), Ministry of Health & Family Welfare, Government of India. Operational Guidelines: Prevention, Screening and Control of Common NCDs. 2023.
How to Cite This Tool
DOIhttps://doi.org/10.5281/zenodo.22401602
AMA Style:Umakanth S. Hypertension Initiation and Titration. Version 1.9. MEDiscuss Clinical Decision Support System. Published 2026. Accessed . https://mediscuss.org/cdss/hypertension-management. doi:10.5281/zenodo.22401602
Vancouver Style:Umakanth S. Hypertension Initiation and Titration [Internet]. Version 1.9. MEDiscuss.org; 2026 [cited ]. Available from: https://mediscuss.org/cdss/hypertension-management. doi:10.5281/zenodo.22401602
Save this calculation
Whatever you type here stays on this device and is not sent anywhere. The server receives only a scrambled code made from it, so nobody with access to the server can tell which patient a saved calculation belongs to. Enter the same nickname the next time to see that patient's earlier values. What is stored
Category Therapeutic & Management PathwaysPathway
Specialties Internal Medicine, Cardiology, Family Medicine
Revision date
Not recorded
Nobody has recorded when this content was last revised, so we cannot tell you how current it is. Check the doses and thresholds against current guidance before you use it.